home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  HIV Therapeutics: Searching for the Next Generation  
  January 31, 2001

Microbiology / Virology

 
     
  SMi Pharma, The Hatton, London, UK
28th February 2001 - 1st March 2001


Day One – Wednesday 28th February 2001

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
Dr Johnson Lau, Senior Vice President, Research & Development, ICN Pharmaceuticals

HIV: THE GLOBAL PICTURE

OVERVIEW OF AIDS AND HIV
9.10 Global trends, epidemiology and opportunities
 Incidence and prevalence of HIV
 Global epidemiology
 Mortality of AIDS: comparison between continents
 Financial impact of HIV infection
 Important considerations in preventing the spread of HIV
 Developing countries
 Unmet needs and opportunities
Dr Hugh McDade, Clinical Development Director, GlaxoWellcome Research &
Development

HIV: STRATEGIC MARKET ANALYSIS
9.40 Predicting future market potential
 The global HIV market
 Pipeline analysis
 Meeting the unmet needs of HIV
 Market forecasts to 2005: identifying the key factors influencing future market developments
 Strategies for success in a competitive market
Natasha Jenkins, Consultant, Infectious Diseases Business Unit, DataMonitor

MECHANISMS OF DISEASE PROGRESSION

DEVELOPING CHEMOKINE-BASED THERAPEUTICS
10.20 case study: ChemoCentryx
 Targeting HIV envelope glycoprotein
 Significance of gp41
 High through-put screening of drug-like compounds for targeting gp41
 Collaborating in the drug discovery programme
Dr Thomas Schall, President & Chief Executive Officer, ChemoCentryx

11.00 Morning Coffee

CHEMOKINES AND THEIR RECEPTORS IN HIV
11.20 Critical components of HIV infection
 Focusing in receptor biology
 Chemokine receptors as cofactors for HIV entry into macrophages and T-cells
 Characterising regions in chemokine receptors interacting with CD4 and gpl20
 The role of chemokines in signalling or inhibiting viral infection and fusion
 Modified chemokine antagonists – proof of concept
 Mechanisms of inhibiting the chemokine-HIV interaction
 Chemokine complexity and problems in designing drug target strategies
 Inhibiting the interaction between the HIV envelope and chemokine receptor as a drug target
 Current status of therapeutics acting via the chemokine system
Dr Amanda Proudfoot, Protein Biochemistry Group Leader, Chemokine Project Leader, Serono Pharmaceutical Research Institute

MEASURING IMMUNE FUNCTION IN HIV PATIENTS
12.00 Case study: Cylex
 The clinical value of measuring immune function
 Identifying when to commence therapy
 Establishing efficacy of therapies
 Determining effectiveness of new vaccines
 In vitro CMITM technology: general principles
 Future development directions for in vitro CMITM
Dr Judith Britz, President & Chief Executive Officer, Cylex

12.40 Networking Lunch

DRUG RESISTANCE

WORKING AGAINST HIV RESISTANCE
2.00 Case study: Biochem Pharma
 Problems of HIV resistance
 Development of BCH-10618
 Mechanisms of action
 Activity of BCH-10618 against HIV strains resistant to nucleoside analogues
Dr Richard Bethell, Associate Director, Virology, Biochem Pharma

HIV RESISTANCE AND PATIENT MANAGEMENT
2.40 A pharmacogenomic approach to improving the efficacy of HIV therapeutics
 The causes of HIV resistance
 Clinical significance of HIV resistance
 Methods employed at Visible Genetics to characterise HIV and determine drug resistance
 Clinical evidence for the value of determining HIV characteristics
 The role of drug resistance testing in patient management
Dr Arthur Cole, Executive Vice President, Visible Genetics

3.20 Afternoon Tea

STRUCTURE BASED APPROACHES TO TAT / TAR INHIBITORS
3.40 Using structural information for the development of RNA-binding drugs
 Ligand/receptor studies by NMR
 RiboDock - modeling for the RNA environment
 Ligand induced conformational changes in RNA - their relevance to drug design
 Cell-free & cell-based assays for inhibitors of the Tat/TAR interaction
Dr David Knowles, Director, Research & Development, RiboTargets

MONOCLONAL ANTIBODIES TO HIV-1 GROUP 0 ENVELOPE
4.20 Specificities to both linear epitopes and to gp41 helix bundle
 Monoclonal antibodies were developed to a recombinant HIV-1 group O envelope protein derived from the HAM 112 isolate
 Antibodies were epitope mapped with use of a series of overlapping peptides covering gp120 C-terminal and gp41 ectodomain regions
 Several antibodies that were non-reactive to individual peptides did however react to a mixture of longer peptides corresponding to the N-terminal and C-terminal regions of the gp41 ectodomain
 These antibodies appear to be reactive to a helical bundle formed by the interaction of the two longer peptides
Dr James Scheffel, Associate Research Fellow, Hybridoma Research, Abbott Laboratories

5.00 Chairman’s Closing Remarks and Close of Day One

5.10 Networking Drinks Reception for Speakers and Delegates

Day Two – Thursday 1st February 2001

8.30 Re-registration & Coffee

9.00 Chairman's Opening Remarks
Dr Paul Von Hoegen, Executive Vice President, Research & Development, Biovector Therapeutics

DRUG THERAPIES AND DEVELOPMENTS

NEW CLASS OF ANTI-VIRAL DRUGS IN PHASE II
9.10 Tripeptides that inhibit HIV-1: discovery and mode of action
 Discovery of anti-HIV-1 tripeptide GPG by a series of mistakes
 GPG blocking of HIV-1 capsid morphogenesis
 Design of other anti-HIV tripeptides that block capsid assembly
 Pharmacokinetics and pharmacodynamics of GPG
 Unexpected results in the kinetics of virus load reduction obtained in the phase I clinical trials
Dr Anders Vahlne, Vice President & Head of Research, Tripep AB

DEVELOPING AND TRIALING IMMUNE BASED THERAPIES (IBT) FOR HIV DISEASE
9.40 Targeting the macrophage in HIV and HCV disease
 Understanding the specific role of the macrophages in HIV infection
 Macrophage changes in HIV infection
 Trialing WF10: a chlorite based drug
 Using WF10 to induce or augment the expression of the alternative activation pathway in macrophages
 Objectives of the trial
 Evaluating the safety and efficacy of WF10
 The rationale for WF10 in HIV disease
Dr Michael McGrath, Chief Scientific Officer, OXO Chemie

TESTING NEW CLASSES OF DRUGS IN HIV
10.20 T-20 & T-1249: a new class of anti-retroviral drugs
 Market for drugs in treatment experienced patients
 Can subcutaneous drugs be marketed in HIV medicine?
 Ethical considerations for trial design in very experienced patients
 How to test for differences if the comparator arm is an ‘optimised background’ therapy
 Expanded access – do we still need these programmes?
Dr Christiane Möcklinghoff, Medical Manager, HIV, Hoffmann-La Roche

11.00 Morning Coffee

ADOPTIVE IMMUNOTHERAPY OF HIV INFECTION USING GENETICALLY TARGETED T-CELLS
11.20 Case study: Cell Genesys
 Background on T-cell adoptive immunotherapy of cancer and viral infections
 Redirecting T-cells using HIV-specific chimeric immune receptors
 Optimization of ex vivo T-cell growth and gene transfer techniques at clinical scale
 Clinical trials of HIV-directed T-cell immunotherapy using CD4-zeta modified CD4 and CD8 T-cells.
Dr Kristen Hege, Director, Clinical Research, Cell Genesys

VACCINES

MVA F6 AS A THERAPEUTIC VACCINE
12.00 Issues and therapeutic approaches
 Are all MVA vectors the same?
 Safety issues for a HIV vaccine vector
 Possible therapeutic approaches for HIV
 MVA F6 clinical up-date
Dr Paul Chaplin, Director of Immunology, Bavarian Nordic GmbH

12.40 Networking Lunch

IMPROVING VACCINE PERFORMANCE WITH ADJUVANTS
2.00 History, evaluation and testing
 History of adjuvants
 Advantages of the use of immunologic adjuvants in vaccine formulations
 Mechanisms of action of vaccine adjuvants
 Immunologic evaluation of adjuvants
 Preclinical safety testing of vaccines formulated with novel adjuvants
Dr Frederick R Vogel, Formulation Platform Leader, Product Development, Aventis- Pasteur

DEVELOPING LIPOPEPTIDE BASED VACCINES TO HIV AND BEYOND
2.40 Strategies and clinical experiences
 Strategies for anti-HIV pharmaccines
 Approaches to increase immunogenicity by lipioation
 Targeting and efficient delivery to mucosal surfaces
 From mouse to man: from model to reality
 Clinical experiences
Dr Paul Von Hoegen, Executive Vice President, Research & Development, Biovector Therapeutics

IMMUNOPROPHYLAXIS, IMMUNOTHERAPY, AND A SYNTHETIC AIDS VACCINE
3.20 Targeting HIV receptors
 MAb B4 neutralises HIV primary isolates (selected from subtypes A-G), HIV-2, SIV, and SHIV
 MAb B4 treatment protects hu-PBL-SCID mice from infection by HIV-1 AD-6 and chimpanzees from infection by HIV-1 DH12 in both pre- and post-exposure modes
 MAb B4 treatment alters the viral kinetics in plasma in chimpanzees infected with HIV-1 DH12 virus in an immunotherapy model
 A continuous B cell site on the CDR2-like domain of CD4 was rendered immunogenic by linkage to UBI immunostimulatory Th sites and elicits neutralising antibodies against HIV-1 primary isolates
 Antibodies to the B cell site block the MAb B4 recognition site by steric hindrance and have the same broad pattern of neutralisation as anti-receptor complex antibody MAb B4
 UBITh peptide immunogens were broadly immunogenic: evoking neutralising antibodies in 3 species including a primate species
 The site-specific CD4 immunogens were not overtly immunosuppressive in the primate and thus, can be used as cell-directed immunotherapeutic vaccine
Dr Chang Yi Wang, President & Chief Executive Officer, United Biomedical

4.00 Chairman's Closing Remarks and Close of Conference

4.10 Afternoon Tea
Workshop

HIV Drug Resistance: Genotyping & Therapeutic Guidance
27th February 2001, The Hatton, London

For treatment experienced patients, HIV genotyping is becoming an essential factor in the design of an effective drug regimen for those individuals who are experiencing therapeutic failure. Even for treatment naïve patients it may be valuable when the circumstances indicate possible infection from a source of resistant virus. Besides it clinical use as a key determinant in drug selection, viral genotyping is also applicable to antiviral drug design and clinical trials of new candidate drugs.

The most comprehensive approach to predicting viral drug resistance, besides costly and time-consuming phenotyping, is to sequence the major sites of anti retroviral drug action: the protease and reverse transcriptase genes of the viral RNA genome.

This workshop examines the theoretical principles and practical applications of the Applied Biosystems ViroSeqTM HIV Genotyping system, a unified reagent and software package that allows rapid and accurate definition of viral genotype from patient blood samples. There will be an opportunity for attendees to use the typing software hands on if they wish, and the use of the sequence data output to obtain clinically useful therapeutic guidelines regarding viral drug resistance will be demonstrated.

1.00 Registration & Coffee & informal introduction

1.30 The ViroSeqTM HIV Genotyping System – design and use

2.30 HIV genotyping software – demonstrating and hands on use

3.30 Break: informal discussion

4.00 Use of HIV genotype data to gain clinical guidance

4.30 Discussion and review of the workshop

About your workshop leader

Ged Murphy, BSc has worked for the company for three years as a technical specialist, with a special emphasis on the support of our infectious and inherited disease products. Prior to joining Applied Biosystems, he worked in a research post at the Blond McIndoe Research Institute in Sussex, and for several years in transplantation research at the Institute for Child Health in Central London.

Dave Watts, BSc, PhD has worked for the company for ten years as a technical specialist, more recently moving to a role in support and administration for our infectious and inherited disease products. Before this he undertook research work in metabolism at Charing Cross Hospital in London and in molecular biology at the National Institute for Medical Research, North London.

Applied Biosystems, formally known as PE Biosystems, is the leading supplier of life science technologies. We develop, market and support systems consisting of instruments, reagents and software that are used in basic life science research and development, diagnostics, forensics and food testing
 
 
Organized by: Katherine Britton, Deputy Head of Pharma Conferences, SMi Ltd
Invited Speakers:  Dr Hugh McDade, Clinical Development Director, GlaxoWellcome Research & Development
 Dr Christiane Möcklinghoff, Medical Manager, HIV, Hoffmann-La Roche
 Dr James Scheffel, Associate Research Fellow, Hybridoma Research, Abbott Laboratories
 Dr Frederick R Vogel, Formulation Platform Leader, Product Development, Aventis-Pasteur
 Dr Amanda Proudfoot, Protein Biochemistry Group Leader, Chemokine Project Leader, Serono Pharmaceutical Research Institute
 Dr Arthur Cole, Executive Vice President, Visible Genetics
 Dr Richard Bethell, Associate Director, Virology, Biochem Pharma
 Dr Michael McGrath, Chief Scientific Officer, OXO Chemie
 Prof Anders Vahlne, Vice President, Head of Research, Tripep AB
 Dr Judith Britz, President & Chief Executive Officer, Cylex
 Natasha Jenkins, Consultant, Infectious Diseases Unit, DataMonitor
 Dr Kristen Hege, Director, Clinical Research, Cell Genesys
 Dr Chang Yi Wang, President & Chief Executive Officer, United Biomedical
 Dr David Knowles, Director, Research & Development, RiboTargets
 Dr Paul Von Hoegen, Executive Vice President, Research & Development, Biovector Therapeutics
 Dr Thomas Schall, President & Chief Executive Officer, ChemoCentryx
 Dr Paul Chaplin, Director of Immunology, Bavarian Nordic GmbH
 
Deadline for Abstracts: Conference is now final, no speaking places left
 
Registration: Register online at www.smi-online.co.uk/hiv.asp
or telephone +44 (0) 20 7252 2222
or email: customer_services@smi-online.co.uk
E-mail: customer_services@smi-online.co.uk
 
  Posted by:   Katherine Britton  
Host: 213.38.112.46
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2001 HUM-MOLGEN. All rights reserved. Liability and Copyright.